|
1
|
Dai Z, Tang H, Pan Y, Chen J, Li Y and Zhu
J: Gene expression profiles and pathway enrichment analysis of
human osteosarcoma cells exposed to sorafenib. FEBS Open Bio.
8:860–867. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Qian M, Gong H, Yang X, Zhao J, Yan W, Lou
Y, Peng D, Li Z and Xiao J: MicroRNA-493 inhibits the proliferation
and invasion of osteosarcoma cells through directly targeting
specificity protein 1. Oncol Lett. 15:8149–8156. 2018.PubMed/NCBI
|
|
3
|
Jaenisch R and Bird A: Epigenetic
regulation of gene expression: How the genome integrates intrinsic
and environmental signals. Nat Genet. 33:245–254. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Suzuki H, Gabrielson E, Chen W, Anbazhagan
R, van Engeland M, Weijenberg MP, Herman JG and Baylin SB: A
genomic screen for genes upregulated by demethylation and histone
deacetylase inhibition in human colorectal cancer. Nat Genet.
31:141–149. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Feller L, Kramer B and Lemmer J:
Pathobiology of cancer metastasis: A short account. Cancer Cell
Int. 12:242012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yoo CB and Jones PA: Epigenetic therapy of
cancer: Past, present and future. Nat Rev Drug Discov. 5:37–50.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hellebrekers DM, Jair KW, Viré E, Eguchi
S, Hoebers NT, Fraga MF, Esteller M, Fuks F, Baylin SB, van
Engeland M, et al: Angiostatic activity of DNA methyltransferase
inhibitors. Mol Cancer Ther. 5:467–475. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deroanne CF, Bonjean K, Servotte S, Devy
L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens
BV, et al: Histone deacetylases inhibitors as anti-angiogenic
agents altering vascular endothelial growth factor signaling.
Oncogene. 21:427–436. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carmeliet P: Angiogenesis in life, disease
and medicine. Nature. 438:932–936. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hsu YY, Shi GY, Wang KC, Ma CY, Cheng TL
and Wu HL: Thrombomodulin promotes focal adhesion kinase activation
and contributes to angiogenesis by binding to fibronectin.
Oncotarget. 7:68122–68139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li T, Kang G, Wang T and Huang H: Tumor
angiogenesis and anti-angiogenic gene therapy for cancer. Oncol
Lett. 16:687–702. 2018.PubMed/NCBI
|
|
12
|
Tan KB, Harrop J, Reddy M, Young P,
Terrett J, Emery J, Moore G and Truneh A: Characterization of a
novel TNF-like ligand and recently described TNF ligand and TNF
receptor superfamily genes and their constitutive and inducible
expression in hematopoietic and non-hematopoietic cells. Gene.
204:35–46. 1997. View Article : Google Scholar
|
|
13
|
Zhai Y, Ni J, Jiang GW, Lu J, Xing L,
Lincoln C, Carter KC, Janat F, Kozak D, Xu S, et al: VEGI, a novel
cytokine of the tumor necrosis factor family, is an angiogenesis
inhibitor that suppresses the growth of colon carcinomas in vivo.
FASEB J. 13:181–189. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kitson J, Raven T, Jiang YP, Goeddel DV,
Giles KM, Pun KT, Grinham CJ, Brown R and Farrow SN: A
death-domain-containing receptor that mediates apoptosis. Nature.
384:372–375. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Migone TS, Zhang J, Luo X, Zhuang L, Chen
C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JXH, et al: TL1A is a
TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell
costimulator. Immunity. 16:479–492. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chinnaiyan AM, O'Rourke K, Yu GL, Lyons
RH, Garg M, Duan DR, Xing L, Gentz R, Ni J and Dixit VM: Signal
transduction by DR3, a death domain-containing receptor related to
TNFR-1 and CD95. Science. 274:990–992. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bai C, Connolly B, Metzker ML, Hilliard
CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP, et
al: Overexpression of M68/DcR3 in human gastrointestinal tract
tumors independent of gene amplification and its location in a
four-gene cluster. Proc Natl Acad Sci USA. 97:1230–1235. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamanegi K, Kawabe M, Futani H, Nishiura
H, Yamada N, Kato-Kogoe N, Kishimoto H, Yoshiya S and Nakasho K:
Sodium valproate, a histone deacetylase inhibitor, modulates the
vascular endothelial growth inhibitor-mediated cell death in human
osteosarcoma and vascular endothelial cells. Int J Oncol.
46:1994–2002. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
20
|
Bolden JE, Peart MJ and Johnstone RW:
Anticancer activities of histone deacetylase inhibitors. Nat Rev
Drug Discov. 5:769–784. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Siu LL, Pili R, Duran I, Messersmith WA,
Chen EX, Sullivan R, MacLean M, King S, Brown S, Reid GK, et al:
Phase I study of MGCD0103 given as a three-times-per-week oral dose
in patients with advanced solid tumors. J Clin Oncol. 26:1940–1947.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schrump DS, Fischette MR, Nguyen DM, Zhao
M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Kruchin E, et al:
Clinical and molecular responses in lung cancer patients receiving
Romidepsin. Clin Cancer Res. 14:188–198. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu S, Ren J, Chen HB, Wang Y, Liu Q, Zhang
R, Jiang SW and Li J: Cytostatic and apoptotic effects of DNMT and
HDAC inhibitors in endometrial cancer cells. Curr Pharm Des.
20:1881–1887. 2014. View Article : Google Scholar
|
|
24
|
Chavez-Blanco A, Perez-Plasencia C,
Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco
B, Taja-Chayeb L, Trejo-Becerril C, Gonzalez-Fierro A, Candelaria
M, et al: Antineoplastic effects of the DNA meth-ylation inhibitor
hydralazine and the histone deacetylase inhibitor valproic acid in
cancer cell lines. Cancer Cell Int. 6:22006. View Article : Google Scholar
|
|
25
|
Bauman J, Shaheen M, Verschraegen CF,
Belinsky SA, Houman Fekrazad M, Lee FC, Rabinowitz I,
Ravindranathan M and Jones DV Jr: A phase I protocol of hydralazine
and valproic acid in advanced, previously treated solid cancers.
Transl Oncol. 7:349–354. 2014. View Article : Google Scholar
|
|
26
|
Capobianco E, Mora A, La Sala D, Roberti
A, Zaki N, Badidi E, Taranta M and Cinti C: Separate and combined
effects of DNMT and HDAC inhibitors in treating human multi-drug
resistant osteosarcoma HosDXR150 cell line. PLoS One. 9:e955962014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takami N, Osawa K, Miura Y, Komai K,
Taniguchi M, Shiraishi M, Sato K, Iguchi T, Shiozawa K, Hashiramoto
A, et al: Hypermethylated promoter region of DR3, the death
receptor 3 gene, in rheumatoid arthritis synovial cells. Arthritis
Rheum. 54:779–787. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kaya M, Wada T, Akatsuka T, Kawaguchi S,
Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F and Ishii S:
Vascular endothelial growth factor expression in untreated
osteosarcoma is predictive of pulmonary metastasis and poor
prognosis. Clin Cancer Res. 6:572–577. 2000.PubMed/NCBI
|
|
29
|
Qu Y, Xu J, Jiang T, Zhao H, Gao Y, Zheng
C and Shi X: Difference in pre- and postchemotherapy vascular
endothelial growth factor levels as a prognostic indicator in
osteosarcoma. J Int Med Res. 39:1474–1482. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chelluri R, Caza T, Woodford MR, Reeder
JE, Bratslavsky G and Byler T: Valproic acid alters angiogenic and
trophic gene expression in human prostate cancer models. Anticancer
Res. 36:5079–5086. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang C, Yang C, Feldman MJ, Wang H, Pang
Y, Maggio DM, Zhu D, Nesvick CL, Dmitriev P, Bullova P, et al:
Vorinostat suppresses hypoxia signaling by modulating nuclear
translocation of hypoxia inducible factor 1 alpha. Oncotarget.
8:56110–56125. 2017.PubMed/NCBI
|
|
32
|
Cinatl J Jr, Kotchetkov R, Blaheta R,
Driever PH, Vogel JU and Cinatl J: Induction of differentiation and
suppression of malignant phenotype of human neuroblastoma BE(2)-C
cells by valproic acid: Enhancement by combination with
interferon-alpha. Int J Oncol. 20:97–106. 2002.
|
|
33
|
Yang GL, Zhao Z, Qin TT, Wang D, Chen L,
Xiang R, Xi Z, Jiang R, Zhang ZS, Zhang J, et al: TNFSF15 inhibits
VEGF-stimulated vascular hyperpermeability by inducing VEGFR2
dephosphorylation. FASEB J. 31:2001–2012. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qi JW, Qin TT, Xu LX, Zhang K, Yang GL, Li
J, Xiao HY, Zhang ZS and Li LY: TNFSF15 inhibits vasculogenesis by
regulating relative levels of membrane-bound and soluble isoforms
of VEGF receptor 1. Proc Natl Acad Sci USA. 110:13863–13868. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang K, Cai HX, Gao S, Yang GL, Deng HT,
Xu GC, Han J, Zhang QZ and Li LY: TNFSF15 suppresses VEGF
production in endothelial cells by stimulating miR-29b expression
via activation of JNK-GATA3 signals. Oncotarget. 7:69436–69449.
2016.PubMed/NCBI
|
|
36
|
Deng HT, Liu HL, Zhai BB, Zhang K, Xu GC,
Peng XM, Zhang QZ and Li LY: Vascular endothelial growth factor
suppresses TNFSF15 production in endothelial cells by stimulating
miR-31 and miR-20a expression via activation of Akt and Erk
signals. FEBS Open Bio. 7:108–117. 2016. View Article : Google Scholar
|
|
37
|
Spina E and Perugi G: Antiepileptic drugs:
Indications other than epilepsy. Epileptic Disord. 6:57–75.
2004.PubMed/NCBI
|
|
38
|
Kandler MR, Mah GT, Tejani AM and Stabler
SN: Hydralazine for essential hypertension. Cochrane Database Syst
Rev. 8:CD0049342010.
|
